Pamela Palasanthiran

Dr. Pamela Palasanthiran

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Vaccine
Verified
Journal Article
Closed access
JNJames Newcombe
James Newcombe
RKRajneesh Kaur
Rajneesh Kaur
NWNicholas Wood
Nicholas Wood
HSHolly Seale
Holly Seale
PPPamela Palasanthiran
Pamela Palasanthiran
TSTom Snelling
Tom Snelling

1 May 2018 in Journal of Clinical Virology
Verified
Journal Article
Closed access
WRWiliam Rawlinson
Wiliam Rawlinson
PPPamela Palasanthiran
Pamela Palasanthiran
BHBeverly Hall
Beverly Hall
LYLaila Al Yazidi
Laila Al Yazidi
MCMichael J. Cannon
Michael J. Cannon
MWMonica Wilkinson
Monica Wilkinson

1 November 2018 in Journal of Clinical Virology
Verified
Journal Article
Closed access
Adam BartlettAdam Bartlett
Adam Bartlett
BHBeverley M. Hall
Beverley M. Hall
PPPamela Palasanthiran
Pamela Palasanthiran
BMBrendan McMullan
Brendan McMullan
ASAntonia W. Shand
Antonia W. Shand
WRWiliam Rawlinson
Wiliam Rawlinson

6 April 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
LMLily Minihan
Lily Minihan
JOJu Mbbs Lee Oei
Ju Mbbs Lee Oei
BBBarbara Bajuk
Barbara Bajuk
PPPamela Palasanthiran
Pamela Palasanthiran
Background: To determine the characteristics and outcomes of postnatal cytomegalovirus (pCMV) infection in preterm infants in a neonatal intensive care unit (NICU). Methods: A retrospective, matched case-control study in a tertiary NICU. Infants born between January 2009 and December 2019, <32 weeks’ gestational age (GA) and/or birth weight (BW) <1500 g with pCMV infection were matched 1:1 with cytomegalovirus-(CMV)-negative infants by year of admission, gender, GA and BW. Primary outcome was death ≤36 weeks’ postmenstrual age or bronchopulmonary dysplasia (BPD). Secondary outcomes were length of ventilation (LOV), length of stay (LOS) and neurodevelopmental impairment (NDI) at corrected age 1 and 2 years. Results: Forty-eight pCMV-positive infants (median GA 25.3 weeks, BW 695 g, age 58 days) were identified from 1659 infants (incidence 2.9%). The most common symptoms of pCMV infection were abdominal distension (43.8%), sepsis-like syndrome (29.2%), thrombocytopenia (60.5%) and conjugated hyperbilirubinemia (60.9%). Compared with controls, there were no significant differences in the composite outcome of death or BPD (56.3% vs. 37.5%; P = 0.1) or NDI at 1 and 2 years (51.9% vs. 44%; P = 0.8; 71.4% vs. 50%; P = 0.4). pCMV-positive infants had a significantly longer median LOV (23.5 vs. 12 days)* and LOS (140 vs. 110.5 days)*. Eleven (22.9%) infants received antivirals. Ten improved and 1 died. Two untreated infants died (1 from pCMV infection). Conclusions: Clinically identifiable pCMV infections are significant and associated with increased respiratory support and prolonged hospital stay in vulnerable infants. pCMV screening and preventive measures against transmission merit consideration. *P < 0.05.

30 June 2023 in Neonatology
Verified
Journal Article
Closed access
PDF file
STSarah Jane Corpuz Tapawan
Sarah Jane Corpuz Tapawan
BBBarbara Bajuk
Barbara Bajuk
JOJu-Lee Oei
Ju-Lee Oei
PPPamela Palasanthiran
Pamela Palasanthiran
NSNsw
Nsw
TGthe ACT Neonatal Intensive Care Units (NICUS) Group
the ACT Neonatal Intensive Care Units (NICUS) Group
Introduction: Reports on the influence of postnatal cytomegalovirus (pCMV) infection in neonatal outcomes of preterm babies vary while guidance on management including screening is lacking. We aim to determine the association between symptomatic pCMV infection and chronic lung disease (CLD) and mortality in preterm infants born less than 32 weeks gestation. Methods: We used data from the Neonatal Intensive Care Units’ (NICUS) population-based prospective data registry of infants in 10 neonatal units in New South Wales and the Australian Capital Territory, Australia. De-identified perinatal and neonatal outcome data for 40,933 infants were examined. We identified 172 infants <32 weeks gestation with symptomatic pCMV infection. Each was matched with one control infant. Results: Infants with symptomatic pCMV infection were 2.7 times more likely to develop CLD (OR 2.7, 95% CI: 1.7–4.5) and spend 25.2 days more in hospital (95% CI: 15.2–35.2). Seventy-five percent (129/172) of infants with symptomatic pCMV were extremely preterm (<28 weeks). The mean age of symptomatic pCMV diagnosis was 62.5 ± 20.5 days or 34.7 ± 3.6 weeks-corrected gestational age. Ganciclovir treatment did not decrease CLD and death. CLD was 5.5 times predictive of death in patients with symptomatic pCMV infection. Symptomatic pCMV infection did not influence mortality nor increase neurologic impairment. Conclusion: Symptomatic pCMV is a modifiable factor affecting extreme preterm infants with significant impact on CLD. Prospective study on screening and treatment will help unveil potential benefits in our already at-risk preterm infants.

12 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DNDaniel A. Norman
Daniel A. Norman
MDMargie Danchin
Margie Danchin
CBChristopher C. Blyth
Christopher C. Blyth
PPPamela Palasanthiran
Pamela Palasanthiran
DTDavid Tran
David Tran
HSHolly Seale
Holly Seale
Introduction: Influenza vaccination of children with medical comorbidities is critical due their increased risks for severe influenza disease. In Australia, hospitals are an avenue for influenza vaccine delivery to children with comorbidities but are not always effectively utilised. Qualitative enquiry sought to ascertainment the barriers and enablers for influenza vaccination recommendation, delivery, and recording of these children at Australian hospitals. Methods: Semi-structured interviews and discussion group sessions were conducted with paediatricians and nurses at four tertiary paediatric specialist hospitals and two general community hospitals in three Australian states. Transcripts from interviews and group sessions were inductively analysed for themes. The Capability, Opportunity, Motivation, and Behaviour (COM-B) model was used to explore the elements of each theme and identify potential interventions to increase influenza vaccination recommendation and delivery behaviours by providers. Results: Fifteen discussion sessions with 28 paediatricians and 26 nurses, and nine in-depth interviews (five paediatricians and four nurses) were conducted. Two central thematic domains were identified: 1. The interaction between hospital staff and parents/patients for influenza vaccine recommendation, and 2. Vaccination delivery and recording in the hospital environment. Six themes across these domains emerged detailing the importance of dedicated immunisation services, hospital leadership, paediatricians’ vaccine recommendation role, the impact of comorbidities, vaccination recording, and cocooning vaccinations. Supportive hospital leadership, engaged providers, and dedicated immunisation services were identified as essential for influenza vaccination of children with comorbidities in Australian hospital. Conclusion: Recommendation of influenza vaccination for Australian children with comorbidities is impacted by the beliefs of paediatricians and the perceived impact of influenza disease on children’s comorbidities. Dedicated immunisation services and supportive hospital leadership were drivers for influenza vaccine delivery at hospitals. Future interventions targeting hospital-based influenza vaccine delivery for children with comorbidities should take a rounded approach targeting providers’ attitudes, the hospital environment and leadership support.